secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001615219-25-000040
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius amends merger fixing 14.1% legacy ownership; Nasdaq delisting risk from $2.5M equity shortfall
--------------------------------------------------------------------------------

- Amendment eliminates cash-based exchange ratio adjustment; legacy Salarius stockholders retain 14.1%, Decoy holders 85.9% of combined company.
- Nasdaq notified Salarius on March 26, 2025 it fails minimum $2.5M stockholders' equity for continued listing.
- Company must submit a compliance plan by May 12, 2025; if accepted, Nasdaq may grant up to 180 days to regain compliance.
- If plan rejected or compliance not regained, Nasdaq may delist; Salarius can request a hearing for up to 180 additional days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000040/0001615219-25-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000040/flks-20250326.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer